

Assessing the likelihood of needing a substance called surfactant for newborns born near their expected delivery date using lung ultrasound

Submission date 23/12/2023	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 02/01/2024	Overall study status Completed	<input checked="" type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 14/06/2024	Condition category Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Lung ultrasound is a non-invasive, easy and quick technique that is being increasingly used in the clinical practice worldwide. It has been proven to be very accurate to evaluate the severity of respiratory failure and the need for surfactant replacement in preterm and extremely preterm neonates. Nonetheless, it is unclear if it is equally accurate and useful to predict surfactant need in late preterm and term neonates, as they may be affected by different types of respiratory failure.

Who can participate?

Late preterm and term (i.e. beyond 34 weeks' gestation) may be enrolled in this study

What does the study involve?

The study is performed within the usual routine care in the participating centres. The results of lung ultrasound will be collected together with the data registered during the standard monitoring of these patients.

What are the possible benefits and risks of participating?

Participation in the study will be useful and bring benefits on a larger scale since it may significantly improve the management of these patients.

No test is performed solely for study purposes and there is no risk whatsoever for the patients. On the contrary, lung ultrasound is non-invasive and is already used in clinical practice to visualise the lungs and have more insights about the respiratory disorder.

Where is the study run from?

APHP-Paris Saclay University DMU2 (France)

Università degli Studi di Padova (Italy)-Dpt di Pediatria

NICU, Hospital Universitario "Puerta del Mar" Cadiz (Spain)

NICU, Dept of Pediatrics, Stanford University (Palo Alto-CA, USA)

NICU, Federico II University Napoli (Italy)

When is the study starting and how long is it expected to run for?
June 2021 to December 2023

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Prof. Daniele De Luca (MD, PhD), daniele.deluca@aphp.fr

Contact information

Type(s)
Public, Scientific, Principal Investigator

Contact name
Prof Daniele De Luca

ORCID ID
<http://orcid.org/0000-0002-3846-4834>

Contact details
Hospital A.Beclere
Clamart
France
92140
+33 145374837
daniele.deluca@aphp.fr

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
Nil known

Study information

Scientific Title
Quantitative lung ultrasound to predict surfactant need in late preterm and term neonates with respiratory failure

Acronym
ULTRAS

Study objectives

A previously validated and well known neonatal lung ultrasound score can predict the surfactant need in late preterm and term neonates with respiratory failure in the first 72h of life with at least the same accuracy shown in preterm neonates.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 30/06/2022, Comitato Etico per la Sperimentazione Clinica della Provincia di Padova (via Giustiniani 1, Padova, 35128, Italy; +39 498211435; luca.bonadies@unipd.it), ref: 5495/AO/22

Study design

Prospective observational pragmatic non-invasive international multi-center cohort study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Diagnostic

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet.

Health condition(s) or problem(s) studied

Surfactant need in late preterm and term infants

Interventions

Calculation of the lung ultrasound scores performed upon NICU admission and before surfactant administration (if any) together with the consideration of data issued of vital monitoring. Ultrasound and monitoring are performed within the routine clinical care in the participating centers (so that no test is performed solely for study purposes) and the study is pragmatically "nested" within clinical care.

Intervention Type

Other

Primary outcome measure

Upon NICU admission and before surfactant administration (if any):

1. Diagnostic accuracy measures (area under the ROC curve and derived accuracy variables). For these outcomes, lung ultrasound scores and need for surfactant replacement will be collected (i.

e.: this will allow the raw calculation of true and false positives and negatives).

2. Additionally demographics, clinical and monitoring variables usually registered during routine care will be collected.

Secondary outcome measures

Oxygenation metrics measured with usual vital monitoring available in each center and its relationship with lung ultrasound score measured using patient records upon NICU admission and before surfactant administration (if any)

Overall study start date

01/06/2021

Completion date

20/12/2023

Eligibility

Key inclusion criteria

All late preterm and term (≥ 34 weeks' gestation) neonates admitted to the NICU in the first 72 h of life with respiratory failure

Participant type(s)

Patient

Age group

Neonate

Sex

Both

Target number of participants

142

Total final enrolment

157

Key exclusion criteria

1. Major congenital malformations or chromosomopathies
2. Airleaks preventing a comprehensive lung ultrasound examination
3. Early onset sepsis and hemodynamic instability (defined as need for any inotrope)
4. Congenital surfactant anomalies
5. Pulmonary hypoplasia or congenital lung malformations
6. PPHN
7. Need for surgery in the first week of life

Date of first enrolment

01/12/2022

Date of final enrolment

20/12/2023

Locations

Countries of recruitment

France

Italy

Spain

United States of America

Study participating centre

APHP-Paris Saclay University, "Beclere" medical center

157 rue de la Porte de Trivaux

Clamart

France

92140

Study participating centre

Azienda Ospedaliero-Universitaria di Padova

V.le Giustiniani 2

Padova

Italy

35128

Study participating centre

Azienda Ospedaliero-Universitaria "Federico II"

Via Sergio Pansini, 5

Napoli

Italy

80131

Study participating centre

Hospital Universitario Puerta del Mar

Avenida Ana de Viya 21

Cadiz

Spain

11009

Study participating centre

Lucile Packard Children's Hospital - Stanford University
725 Welch Road, Palo Alto, CA
Palo Alto (CA)
United States of America
94304

Sponsor information

Organisation

APHP-Paris Saclay University DMU2

Sponsor details

157 rue de la Porte de Trivaux
Clamart (Paris)
France
92140
+33 145374837
alexandra.benachi@aphp.fr

Sponsor type

Hospital/treatment centre

Funder(s)

Funder type

Other

Funder Name

Investigator initiated and funded

Results and Publications

Publication and dissemination plan

Planned publication in high-impact journals and partial data presentation at the main North-America and European NICU congresses

Intention to publish date

01/06/2024

Individual participant data (IPD) sharing plan

The whole dataset used in the study will be available from the study coordinator (Prof. Daniele De Luca (MD, PhD) - daniele.deluca@aphp.fr) upon reasonable request with clear aims and respecting privacy regulation.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Statistical Analysis Plan			28/12/2023	No	No
Results article		01/05/2024	14/06/2024	Yes	No